DRugwatch BlogRSS 2.0

DRugwatch Blog > September 2010 > A Turbulent Time in Castrate-Resistant Prostate Cancer – Success and Failures of Late-Stage Emerging

A Turbulent Time in Castrate-Resistant Prostate Cancer – Success and Failures of Late-Stage Emerging Therapies

Andrew MerronWritten by: Andrew Merron

SUMMARY
The late-stage clinical pipeline for Prostate Cancer (CaP) is diverse and dynamic: news concerning three high-profile emerging agents in Phase III trials for CaP were released during September 2010.

  • On September 9th, Johnson & Johnson announced that the pivotal Phase III trial for abiraterone in chemotherapy-pretreated, metastatic, castrate-resistant CaP (MCRPC) was unblinded based on advice from the Independent Data Monitoring Committee (IDMC). There was a statistically significant improvement in overall survival (OS) in the pre-specified interim analysis.
  • On September 27th, AstraZeneca announced that zibotentan failed to significantly improve OS in a pivotal Phase III study in asymptomatic/minimally symptomatic MCRPC.
  • Finally, also on September 27th, Pfizer announced that the pivotal Phase III trial of Sutent in combination with prednisone for Taxotere-treated MCRPC patients has been discontinued because Sutent would unlikely improve OS.

ANALYSIS
Abiraterone is a highly promising emerging therapy for MCRPC. Decision Resources had forecasted a launch of abiraterone, the recent positive top-line OS results only confirm this agent is still on track to approval. Full data are not yet available but will be presented at the European Society for Medical Oncology (ESMO) conference next month. We forecast abiraterone will be a clinically and commercially successful agent in the treatment of MCRPC, but it also has potential to be used in earlier lines of treatment. Initially, abiraterone will be prescribed to MCRPC patients who have previously received chemotherapy, in this setting it will join Sanofi-Aventis’ newly FDA-approved chemotherapy, Jevtana (cabazitaxel). We forecast that abiraterone will also be approved in first-line asymptomatic/minimally symptomatic MCRPC, where it will compete with Dendreon’s Provenge (sipuleucel-T) for patient share. It is unlikely these two agents will be used concurrently because of the chronic administration of prednisone (an immunosuppressive agent) (a requirement for abiraterone) may reduce the efficacy of Provenge. Oral delivery, proven mechanism of action, and likely lower cost of abiraterone compared with Provenge will help drive uptake of abiraterone in this setting.

Conversely, the failure of zibotentan in asymptomatic/minimally symptomatic MCRPC means zibotentan will not compete with Provenge or abiraterone. Decision Resources forecasted that zibotentan would not launch in this setting, however despite the recently announced failure, two further Phase III trials for zibotentan are ongoing in the ENTHUSE (Endothelin-A Use) clinical program. The failure of zibotentan to significantly improve OS in asymptomatic/minimally symptomatic MCRPC in Phase II and Phase III trials may be due to short treatment durations. Therefore, hope remains for zibotentan in non-metastatic CRPC (as a single agent) and in first-line MCRPC (in combination with Taxotere) because zibotentan will likely be given for extended durations.

Pfizer’s pivotal Phase III trial for Sutent has been discontinued in the chemotherapy-pretreated MCRPC setting. The SUN-1120 trial was evaluating Sutent in combination with prednisone in Taxotere-pretreated MCRPC patients. The trial was discontinued based on advice from the IDMC because OS would unlikely be significantly improved. Decision Resources had forecasted that Sutent would not launch for MCRPC. The failure of Sutent follows in the wake of the March 2010 news that Roche/Genentech/Chugai’s Avastin (bevacizumab) failed to significantly improve OS in first-line MCRPC setting in combination with Taxotere/prednisone. The failure of Sutent further highlights the questionable role of angiogenesis inhibition in the treatment of advanced CaP. Although high unmet need for improving OS in second-line MCRPC remains, cabazitaxel and now abiraterone will help fulfill this need. The failure of Sutent means that abiraterone and cabazitaxel can exploit this underserved population, and the anticipated entry of Medivation/Astellas Pharma’s novel hormonal agent, MDV-3100, will also add to the therapeutic options in this setting.

The scale of abiraterone’s positive OS results is eagerly anticipated. With ESMO just a few weeks away we will see the clinical impact of abiraterone in MCRPC and also learn of other clinical results that will shape the future CaP market.
Posted on: 9/30/2010 3:33:28 PM | with 0 comments


Tags: Andrew Merron, Oncology

Trackback URL: http://decisionresources.com/trackback/2160fcec-e92c-4267-b7ba-063b558fa1dc/A-Turbulent-Time-in-Castrate-Resistant-Prostate-Cancer-–-Success-and-Failures-of-Late-Stage-Emerging.aspx?culture=en-US

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Pfizer Increases Enrollment by 40% in the SPIRE Cardiovascular Outcomes Trials for PCSK9 Inhibitor Bococizumab
Post date:
11/11/2014 9:36:25 AM
Post Summary:
Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).

Post title:
Obesity Week 2014 - Belviq gets the combination treatment
Post date:
11/7/2014 10:07:43 AM
Post Summary:
Gideon HeapContributor: Gideon Heap

Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.


Post title:
What’s going to be Hot at the 2014 AHA Scientific Sessions?
Post date:
10/22/2014 5:22:24 PM
Post Summary:
  Contributor: Conor Walsh

 This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

  • Risk and benefit of dual antiplatelet therapy (DAPT),
  • Anti-lipid therapy and prevention of coronary artery disease,
  • Treatment of structural heart disease
  • Drugs, devices and systems of care for ischemic heart disease.

Post title:
Advancing the Treatment of TKI-refractory NSCLC
Post date:
10/9/2014 1:33:46 PM
Post Summary:
Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

Post title:
Realizing the Potential of HPV-associated Cancer Prevention
Post date:
10/8/2014 10:15:17 AM
Post Summary:
Contributors: Kirsha Naicker and Dan Roberts

HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years.

Decision Resources Group brands include: